Henry Schein, Inc. (NASDAQ:HSIC) Shares Sold by Fiduciary Group LLC

Fiduciary Group LLC lessened its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 13.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,712 shares of the company’s stock after selling 1,000 shares during the quarter. Fiduciary Group LLC’s holdings in Henry Schein were worth $464,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in HSIC. Holocene Advisors LP acquired a new position in shares of Henry Schein in the 3rd quarter worth approximately $58,319,000. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in shares of Henry Schein in the 3rd quarter worth approximately $43,740,000. Southpoint Capital Advisors LP lifted its holdings in shares of Henry Schein by 30.0% in the 3rd quarter. Southpoint Capital Advisors LP now owns 2,600,000 shares of the company’s stock worth $189,540,000 after purchasing an additional 600,000 shares during the last quarter. Bank of Montreal Can lifted its holdings in shares of Henry Schein by 365.6% in the 3rd quarter. Bank of Montreal Can now owns 711,487 shares of the company’s stock worth $52,095,000 after purchasing an additional 558,689 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in shares of Henry Schein in the 4th quarter worth approximately $34,720,000. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Stock Down 0.6 %

Shares of Henry Schein stock opened at $70.45 on Friday. Henry Schein, Inc. has a 1-year low of $63.67 and a 1-year high of $82.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The business’s fifty day moving average price is $74.83 and its two-hundred day moving average price is $72.61. The company has a market capitalization of $8.75 billion, a P/E ratio of 28.99, a PEG ratio of 2.13 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $1.19 EPS for the quarter, missing analysts’ consensus estimates of $1.23 by ($0.04). Henry Schein had a return on equity of 12.90% and a net margin of 2.51%. The firm had revenue of $3.19 billion during the quarter, compared to the consensus estimate of $3.25 billion. During the same period in the prior year, the firm posted $0.66 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. As a group, research analysts forecast that Henry Schein, Inc. will post 4.74 EPS for the current year.

Analysts Set New Price Targets

Several analysts recently issued reports on HSIC shares. Wells Fargo & Company started coverage on Henry Schein in a report on Friday, February 14th. They issued an “equal weight” rating and a $80.00 price target on the stock. Barrington Research reissued an “outperform” rating and issued a $90.00 price target on shares of Henry Schein in a report on Wednesday, February 26th. Jefferies Financial Group raised their price target on Henry Schein from $77.00 to $80.00 and gave the stock a “hold” rating in a report on Thursday, January 23rd. UBS Group cut their price target on Henry Schein from $83.00 to $80.00 and set a “neutral” rating on the stock in a report on Wednesday, February 26th. Finally, Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. Six investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Henry Schein has a consensus rating of “Moderate Buy” and an average target price of $81.10.

Insider Transactions at Henry Schein

In related news, CEO Bradford C. Connett sold 4,036 shares of Henry Schein stock in a transaction on Wednesday, March 19th. The stock was sold at an average price of $71.15, for a total value of $287,161.40. Following the transaction, the chief executive officer now directly owns 62,688 shares in the company, valued at $4,460,251.20. The trade was a 6.05 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Philip A. Laskawy sold 2,604 shares of the stock in a transaction on Wednesday, March 19th. The shares were sold at an average price of $71.04, for a total value of $184,988.16. Following the completion of the transaction, the director now owns 24,805 shares of the company’s stock, valued at $1,762,147.20. This trade represents a 9.50 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 1.14% of the company’s stock.

Henry Schein Company Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.